{"created":"2024-12-03T01:54:25.605763+00:00","id":2002062,"links":{},"metadata":{"_buckets":{"deposit":"89b57833-47d8-4a9a-9baa-e9c802acf324"},"_deposit":{"created_by":8,"id":"2002062","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2002062"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02002062","sets":["1732778801467:1732778962699:1733190542397"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kojima, Manabu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Soeda, Shu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okabe, Chikako","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sato, Tetsu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kamo, Norihito","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ueda, Makiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Endo, Yuta","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Nomura, Shinji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tokuda, Emi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Furukawa, Shigenori","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kataoka, Masao","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Fujita, Shotaro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saji, Shigehira","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Watanabe, Takafumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Fujimori, Keiya","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2022 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-sa/4.0/"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Recurrent Endometrial Cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pelvic Exenteration","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Immune Checkpoint Inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pembrolizumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Surgery can be curative treatment for pelvic locoregional recurrence of endometrial cancer; however, a cure is contingent on complete resection. Here, we report the case of a patient in whom recurrent endometrial tumor remained in the pelvis after resection; long-term control was achieved with postoperative administration of pembrolizumab.The patient had recurrent endometrial cancer of stage IA and was treated with chemotherapy and radiation, but tumor persisted in the pelvic cavity. We therefore attempted total pelvic exenteration, but the tumor was adherent to the pelvic wall and complete resection could not be achieved. However, postoperative administration of pembrolizumab controlled the residual tumor for more than two years without regrowth. We believe that since the resected tumor was MSI-High, the residual tumor responded well to pembrolizumab. It is not known whether cytoreductive surgery contributes to a long-term response to pembrolizumab, but at least in our patient, pembrolizumab appeared to be a very effective drug therapy for MSI-High endometrial cancer that was refractory to chemotherapy and radiotherapy.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"The Fukushima Society of Medical Science","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0016-2590","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2185-4610","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA0065246X","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"195","bibliographicPageStart":"191","bibliographicVolumeNumber":"68","bibliographic_titles":[{"bibliographic_title":"Fukushima Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.5387/fms.2022-10","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"36351631","subitem_relation_type_select":"PMID"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"2024061745","subitem_relation_type_select":"ICHUSHI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2022-12-23"}],"displaytype":"detail","filename":"FksmJMedSci_68_p191.pdf","filesize":[{"value":"768.6 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2002062/files/FksmJMedSci_68_p191.pdf"},"version_id":"4d3cad07-daf3-44bd-b5af-1cb23cbfab79"}]},"item_title":"Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report","item_type_id":"40002","owner":"8","path":["1733190542397"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-12-23"},"publish_date":"2022-12-23","publish_status":"0","recid":"2002062","relation_version_is_last":true,"title":["Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2024-12-03T02:07:23.212539+00:00"}